Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study

Pei-Lung Chen1,2,3,4,5,*, Shyang-Rong Shih1,6,*, Pei-Wen Wang7, Ying-Chao Lin8, Chen-Chung Chu9, Jung-Hsin Lin8,10,11, Szu-Chi Chen1,12, Ching-Chung Chang1,13,14, Tien-Shang Huang1,6,15,16, Keh Sung Tsai1,17,18, Fen-Yu Tseng1, Chih-Yuan Wang1, Jin-Ying Lu1, Wei-Yih Chiu1, Chien-Ching Chang8, Yu-Hsuan Chen10, Yuan-Tsong Chen8,19, Cathy Shen-Jang Fann8, Wei-Shiung Yang1,3,4,5,6 & Tien-Chun Chang1,6

Graves' disease is the leading cause of hyperthyroidism affecting 1.0–1.6% of the population. Antithyroid drugs are the treatment cornerstone, but may cause life-threatening agranulocytosis. Here we conduct a two-stage association study on two separate subject sets (in total 42 agranulocytosis cases and 1,208 Graves' disease controls), using direct human leukocyte antigen genotyping and SNP-based genome-wide association study. We demonstrate HLA-B*38:02 (Armitage trend Pcombined = 6.75 × 10^{-32}) and HLA-DRB1*08:03 (Pcombined = 1.83 × 10^{-9}) as independent susceptibility loci. The genome-wide association study identifies the same signals. Estimated odds ratios for these two loci comparing effective allele carriers to non-carriers are 21.48 (95% confidence interval = 11.13-41.48) and 6.13 (95% confidence interval = 3.28-11.46), respectively. Carrying both HLA-B*38:02 and HLA-DRB1*08:03 increases odds ratio to 48.41 (Pcombined = 3.32 × 10^{-21}, 95% confidence interval = 21.66-108.22). Our results could be useful for antithyroid-induced agranulocytosis and potentially for agranulocytosis caused by other chemicals.
G 

G 

G 

G 

G

raves’ Disease (GD, MIM 27500) is the leading cause of hyperthyroidism, manifested with diffuse goitre, thyroid hyperfunction, thyroid-specific auto-antibodies, ophthalmopathy and/or dermopathy. Its prevalence in the general population is as high as 1.0–1.6%, more common in females. Antithyroid drugs (ATDs, including methimazole, carbimazole and propylthiouracil) are relatively simple molecules known as thionamides, which have been cornerstones of GD treatment across the globe. ATD-induced agranulocytosis, namely thionamide-induced agranulocytosis (TiA, defined as an absolute granulocyte count <500 mm^-3 while taking ATDs), is the most feared adverse effect of ATDs and can occur in 0.1–0.37% of GD patients receiving these medications. Agranulocytosis is life-threatening and can be induced by a variety of non-chemotherapy drugs.

Among the 11 most common offending drugs summarized in a recent review, ATDs accounted for 3 of the 11, and the other drugs included clozapine, dapson, dipyrone, penicillin G, procainamide, rituximab, sulfasalazine and ticlopidine. Drug-induced adverse effects could be broadly categorized into several types, including type A (dose-related, augmented) and type B (non-dose-related, bizarre), and can have different genetic predisposition. TiA belongs to type B. Overall, pharmacogenetic studies related to drug-induced agranulocytosis were scanty and very often were inconclusive.

The other hand, non-genetic risk factors remain elusive as well. Human leukocyte antigen (HLA) genes have been associated with many drug-induced adverse effects, including carbamazepine-induced Stevens–Johnson syndrome (HLA-B*15:02 and HLA-A*31:01), abacavir-induced hypersensitivity syndrome (HLA-B*57:01), lapatinib-induced liver injury (HLA-DQA1*02:01) and so on. Non-HLA genes also cause numerous drug-induced adverse effects through various pharmacokinetic and pharmacodynamic mechanisms. To comprehensively identify HLA and non-HLA genetic susceptibility to TiA, we conducted both direct HLA genotyping and genome-wide association study (GWAS) on GD patients with or without TiA. We demonstrate HLA-B*38:02 and HLA-DRB1*08:03 as independent, major susceptibility loci. Importantly, the GWAS data identify the same HLA signals, as well as one association peak at chromosome 3q13 with borderline significance. Three-dimensional (3D) structure modelling of the two HLA proteins and ATDs provides possible binding modes.

Results

Direct classical HLA loci genotyping and association tests. The structure of the study and the number of participants are summarized in Supplementary Table 1. For HLA association study using six directly genotyped classical HLA loci (HLA-A,-B,-C,-DPB1, -DQB1 and -DRB1), we observed two significant associations at HLA-B*38:02 (P = 1.59 × 10^-3, note: P values are Armitage trend P values in this manuscript, if not otherwise specified) and HLA-DRB1*08:03 (P = 1.24 × 10^-5) in the first-stage study (21 TiA cases versus 662 GD controls). The second-stage study (additional 21 TiA cases versus 546 GD controls) replicated the two associations at HLA-B*38:02 (P = 1.59 × 10^-27) and HLA-DRB1*08:03 (P = 3.91 × 10^-5). Combined results from 42 TiA cases and 1,208 GD controls showed even stronger associations: HLA-B*38:02 (P_{combined} = 6.75 × 10^{-35}) and HLA-DRB1*08:03 (P_{combined} = 1.83 × 10^{-9}, Table 1). The allele frequencies of HLA-B*38:02 were 29.8% in the TiA cases, 3.3% in the GD controls and 3.3% in general population in Taiwan. The allele frequencies of HLA-DRB1*08:03 were 28.6% in the TiA cases, 8.4% in the GD controls and 8.6% in general population. The genotypic information for 42 TiA cases is shown in Supplementary Table 2. The allele frequencies of 6 classical HLA genes in 42 TiA cases and in 1,208 GD controls can be found in Supplementary Data 1. Odds ratios of these two HLA alleles for effective allele carriers compared with non-carriers were 21.48 (95% confidence interval, CI = 11.13–41.48) and 6.13 (95% CI = 3.28–11.46), respectively. These two loci are not in the same linkage disequilibrium (LD) block (Fig. 1 and Supplementary Fig. 1). In addition, HLA-A*02:03, HLA-C*07:02 and HLA-DQB1*06:01 also showed significant association signals (P = 4.22 × 10^-8, 4.09 × 10^-6 and 1.29 × 10^-6, respectively) but were found to be in LD with either HLA-B*38:02 or HLA-DRB1*08:03 (Fig. 1 and Supplementary Fig. 1), therefore not considered as independent associations. HLA imputation using single-nucleotide polymorphisms (SNPs) at the HLA region was also carried out. The results were highly similar to those based on direct HLA typing (Table 2 and Supplementary Table 3).

Genome-wide association study. GWAS using Affymetrix Axiom Genome-Wide CHB 1 SNP Array (a total of 522,980 autosomal SNPs after quality-control process) showed an excess of small P values at the tail of the quantile–quantile distribution plot (Supplementary Fig. 2) but only limited evidence of inflation caused by population stratification (genomic inflation factor λ_{GC} = 1.01). The multidimensional scaling (MDS) and principal component analyses showed no

### Table 1 | Association study in the first stage, second stage and combined stage.

| Chr.   | SNP (position) | Study group     | TIA      | GD controls |
|--------|----------------|-----------------|----------|-------------|
|        |                |                 | n  | RAF  | OR  | (95% CI) | P value  | n  | RAF  | OR  | (95% CI) |
| 6      | HLA-B*38:02 (31232319) | First stage   | 21 | 0.238 | 7.42 | (3.47–15.90) | 1.59 × 10^-9 | 656 | 0.040 | 1.00 |
|        |                 | Second stage   | 21 | 0.357 | 21.91 | (10.48–45.83) | 1.59 × 10^-27 | 546 | 0.025 | 1.00 |
|        |                 | Combined stage | 42 | 0.298 | 12.31 | (7.33–20.67) | 6.75 × 10^-32 | 1202 | 0.033 | 1.00 |
| rs17193122 (31335336) | First stage   | 21 | 0.262 | 5.74 | (2.74–12.02) | 8.18 × 10^-08 | 474 | 0.058 | 1.00 |
|        |                 | Second stage   | 21 | 0.381 | 16.77 | (8.20–34.30) | 1.15 × 10^-24 | 453 | 0.035 | 1.00 |
|        |                 | Combined stage | 42 | 0.321 | 9.59 | (5.78–15.90) | 4.29 × 10^-27 | 927 | 0.047 | 1.00 |
| rs168699525 (32389143) | First stage   | 21 | 0.262 | 4.61 | (2.24–9.67) | 3.83 × 10^-05 | 741 | 0.071 | 1.00 |
|        |                 | Second stage   | 21 | 0.286 | 3.77 | (1.86–7.36) | 8.24 × 10^-05 | 453 | 0.096 | 1.00 |
|        |                 | Combined stage | 42 | 0.274 | 4.16 | (2.50–6.90) | 1.27 × 10^-08 | 927 | 0.083 | 1.00 |
| 6      | HLA-DRB1*08:03 (32552080) | First stage   | 21 | 0.286 | 4.76 | (2.36–9.57) | 1.24 × 10^-05 | 651 | 0.078 | 1.00 |
|        |                 | Second stage   | 21 | 0.286 | 3.96 | (1.97–7.98) | 3.91 × 10^-05 | 545 | 0.092 | 1.00 |
|        |                 | Combined stage | 42 | 0.286 | 4.36 | (2.66–7.15) | 1.83 × 10^-09 | 1196 | 0.084 | 1.00 |

Chr., chromosome; CI, confidence interval; GD, Graves’ Disease; HLA, human leukocyte antigen; OR, odds ratio; RAF, risk allele frequency; TiA, thionamide-induced agranulocytosis.

The physical positions were annotated according to NCBI build 37.1.

OR values were calculated using allelic association test.

P values were calculated using Cochrane-Armitage test for trend.
Although HLA-B*38:02 and HLA-DRB1*08:03 are sometimes in the same extended HLA haplotype, we could demonstrate their independent effects on the basis of three lines of evidence. First, the LD block patterns of TiA cases and GD controls (Fig. 1 and Supplementary Fig. 1) clearly showed that these two alleles resided in two different LD blocks. Second, in our stepwise regression model, these two alleles demonstrated independent effects ($P=1.89 \times 10^{-16}$ for HLA-B*38:02 and $P=2.24 \times 10^{-6}$ for HLA-DRB1*08:03, respectively, Supplementary Table 5). Third, in those individuals who carried HLA-B*38:02 (25 in TiA cases and 77 in GD controls), the percentage of individuals who also carried HLA-DRB1*08:03 was statistically higher in TiA cases (16/25 = 64%) than in GD controls (15/76 = 19.74%, $P=9.44 \times 10^{-5}$).

**Table 2 | Results of conditional association analysis using direct HLA typing and imputation.**

| HLA                | Conditional on | Direct HLA typing: $P$ | Imputed HLA using SNP2HLA: $P$* |
|--------------------|----------------|------------------------|---------------------------------|
| HLA-B*38:02        | HLA-DRB1*08:03 | $1.89 \times 10^{-16}$ | $2.07 \times 10^{-14}$          |
| HLA-DRB1*08:03     |                | $2.24 \times 10^{-6}$  | $1.68 \times 10^{-6}$           |

*SNP2HLA (Jia et al. 2015).

**HLA-B*38:02 and HLA-DRB1*08:03 have major effects.** We observed none of the 42 TiA cases to be homozygous for HLA-B*38:02, and only 2 of them to be homozygous for HLA-DRB1*08:03. Following the traditional practice for assessing the risk of HLA-related drug adverse effect (17,23), we calculated disease odds ratio for these loci according to the effective allele carrier status. HLA-B*38:02 was present in 59.52% of TiA cases, but only in 6.41% of GD controls, which transformed into an odds ratio of 21.48 ($P=6.28 \times 10^{-19}$, 95% CI = 11.13–41.48). HLA-DRB1*08:03 was present in 52.38% of TiA cases, but only in 15.22% of GD controls, which transformed into an odds ratio of 6.13 ($P=1.35 \times 10^{-8}$, 95% CI = 3.28–11.46). For those who carried both HLA-B*38:02 and HLA-DRB1*08:03 (38.10% in TiA cases and 1.26% in GD controls), the odds ratio increased to 48.41 ($P=3.32 \times 10^{-21}$, 95% CI = 21.66–108.22). Using a logistic regression procedure (Supplementary Table 5), the final logistic regression model was:

$$
\logit(\pi) = -4.4936 + 2.6382 \times HLA-B*38:02 + 1.2857 \times HLA-DRB1*08:03 \ (1)
$$

(both loci under additive model), where $\pi$ was the probability of TiA.

Under this model, the AUC of the receiver operating characteristic (ROC) curve was 81.22% (Fig. 3). Since ~74% of the TiA patients carry the risk genotypes and routine follow-up of blood cell count is controversial (3-6), different follow-up protocols can be proposed on the basis of genetic risk stratification to possibly prevent 74% of this rare condition from occurrence. Further replication is needed to confirm the estimate. Cost-effectiveness analysis will be carried out in further study.

**3D structure modelling.** Despite the strong genetic associations, the mechanisms of actions remain enigmatic. To further probe the direct interactions between the HLA proteins and the thionamide drugs, 3D structure modelling, molecular docking and molecular dynamics simulations were carried out to determine the possible binding modes and to estimate the binding affinities of the thionamide–HLA complexes. For HLA-B*38:02 and HLA-

---

**Figure 1 | Regional plot of association signals and LD patterns at the HLA region.** (Top panel): The $x$ axis shows chromosomal positions. The left $y$ axis shows $-\log_{10}P$ values from the GWAS. Colours of the dots indicate the LD relationship between rs17193122 or rs166869525 and their neighbouring SNPs in the 4-Mb region (30–32 Mb for rs17193122 and 32–34 Mb for rs166869525) based on our own data (969 samples). The red dashed line indicates the significance threshold ($9.56 \times 10^{-8}$). The right $y$ axis shows the recombination rate between SNPs calculated based on Asian-ancestry population data from the 1000 Genomes Project. (Bottom panel): LD map based on $r^2$ in the associated regions using genotype results from our own data (969 samples). We construct the plot using the Haploview software version 4.2, and $r^2$ ($\times 100$) values are depicted in the diamonds.

**HLA-B*38:02 and HLA-DRB1*08:03 have independent effects.** The associations at the HLA region derived from two different genotyping techniques (direct classical HLA genotyping and Affymetrix SNP Array) provided convergent evidence of the same signals. The first group of SNPs, represented by rs17193122, were in LD with HLA-B*38:02 (Fig. 1), and their associations with TiA disappeared when they were tested in the regression model containing HLA-B*38:02. Similarly, the second group of SNPs, represented by rs116689525, were in LD with HLA-DRB1*08:03 (Fig. 1), and did not show significant association as well in the regression model containing HLA-DRB1*08:03.
B*38:01 proteins, binding modes in pocket B and pocket F exhibit comparable binding affinities in the range between $-4.48$ and $-6.36$ kcal mol$^{-1}$. It should be noted that the binding of the thionamide drugs could be further stabilized by the peptide to be presented. Examples of specific protein–ligand interactions stabilizing the thionamide–HLA complexes of binding modes with relatively strong affinities are illustrated in Fig. 4. In the molecular dynamics simulations, it was observed that the thionamide drugs drift and anchor to different sub-pockets of the peptide-binding groove with alternating hydrogen bonds and specific contacts. Cys67 of HLA-B*38:02 and HLA-B*38:01, which signifies the polymorphism of these two HLAs, is found to locate in the neighbourhood of the drug-binding sites. Therefore, it is anticipated that the sulphydryl groups of the Cys67 and thionamide drugs may form disulfide bonds under the oxidative condition and thereby further stabilize the drug–HLA complex. However, we also note that one of the major binding poses of methimazole at the pocket B of HLA-B*38:01 would cause steric hindrance for the peptide binding. In pocket F of HLA-B*38:02 and HLA-B*38:01 (Fig. 5), and pocket 9 of HLA-DRA/DRB1*08:03 (Fig. 4e,f), one asparagine residue (Asn77 for HLA-B*38:02 and HLA-B*38:01, and Asn69 for HLA-DRA/DRB1*08:03) was found to play a critical role in stabilizing the drugs at the edge of the peptide-binding groove, by bonding with the sulfur atom or the nitrogen atom (sometimes both) of the drugs. Besides, Thr80 and Tyr123 in HLA-B*38:02, Tyr74 in HLA-B*38:01, Argx76, Tyrβ37 and Serβ57 in HLA-DRA/DRB1*08:03 provide additional interactions to stabilize the drugs in the F pocket. The peptide-binding groove of HLA-DRA/DRB1*08:03 are rich in aromatic residues and polar residues, which could also trap the thionamide drugs in the binding groove. It should be cautiously noted that here we only depict the most frequently occurring binding modes of many possible ones in the dynamics simulations. Since we did not know which peptides would participate in this process, the binding affinity and the binding modes of the drug in the HLA–peptide complex and the determinants of TIA response were not solved at this moment. Further experiments are needed.

Discussion
In this study, we performed concurrent direct HLA genotyping and GWAS in a cohort of 42 TiA cases and 1,208 GD controls in a two-stage study, and identified two HLA loci as major genetic determinants of ATD-induced agranulocytosis. This approach had the advantage of exploring the entire genome without bias and also to use two independent genotyping methods to evaluate the effects of classical HLA genes and other non-HLA genes at the HLA region.

For the HLA associations, we demonstrated that HLA-B*38:02 and HLA-DRB1*08:03 had independent major effects. Class I and class II HLA genes have different structures, cell-type distributions and functional roles in the immune system. Therefore, the genetic susceptibility from both classes for a phenotype is quite intriguing. Before our finding, Lucena et al. already reported the association of class I and class II HLA genotypes with amoxicillin–clavulanate-induced liver injury. How both class I and class II HLA genes confer genetic susceptibility to the same drug adverse effect deserves further pathophysiological investigation.

Several additional analyses were performed intending to relate the genotypes of the TiA cases to other characteristics (Supplementary Tables 6–8). Some interesting signals were picked up, such as age at agranulocytosis (Supplementary Table 6) and ATDs administered (Supplementary Table 8). Because the sample size was small for each genotype, it may be premature to draw any conclusion from these.

In genetic studies, the HLA region is challenging to get clear-cut results because of high gene density, enormous polymorphism and extended LD. Although we demonstrated independent associations between TiA and two classical HLA genes/alleles, namely HLA-B*38:02 and HLA-DRB1*08:03, an association study could not exclude the possibility of nearby non-HLA gene(s) to be the genuine causative gene(s).
Previously, Tamai et al.\textsuperscript{13} reported an association of TiA with HLA-DRB1*08032 (the same allele as HLA-DRB1*08:03) in 1996. It is noteworthy that Japanese population has very low frequency (\(<0.5\%\)) of HLA-B*38:02 (ref. \textsuperscript{27}); therefore, the results from Tamai et al.\textsuperscript{13} further provide evidence supporting the independent effects of HLA-DRB1*08:03 and HLA-B*38:02.

Among all genetic studies of drug-induced agranulocytosis, clozapine-induced agranulocytosis is the most studied\textsuperscript{15,16,23}. HLA-B*38 was associated with clozapine-induced agranulocytosis in Jews, but not in other populations\textsuperscript{15,16,23,28}. HLA-B*38 alleles in Caucasians are mainly HLA-B*38:01, not HLA-B*38:02 popular in Asians\textsuperscript{27}. The two alleles differ by one amino acid at the 80th position (Supplementary Fig. 5) located at peptide-binding groove pocket F\textsuperscript{29}. It is intriguing that two related HLA alleles were associated with agranulocytosis induced by two structurally unrelated drugs.

A couple of caveats need to be addressed. First, the total number of TiA cases in this report was not big. Second, for any single genetic association study, the possibility of population substructure cannot be completely excluded. Although this report is by far the largest TiA genetic study, with the two-stage study design and extensive quality-control steps supporting the validity of the results, it is still crucial to have independent replications in the same and/or other populations in the future.

The susceptibility HLA alleles we discovered (HLA-B*38:02 and HLA-DRB1*08:03) have higher allele frequencies in Asians (0.036 and 0.048, respectively) than in Caucasians (0.004 and 0.002, respectively)\textsuperscript{27}. However, the incidence of TiA, according to available surveys, seems to be similar across the globe\textsuperscript{4–6,30,31}. Therefore, these two alleles cannot be the only reason for TiA susceptibility. There are several possible explanations supported by examples from other diseases. For example, the major susceptibility HLA alleles in different populations might be structurally similar alleles, such as different HLA-DR4 alleles (HLA-DRB1*04:01 and HLA-DRB1*04:05) for type 1 diabetes susceptibility\textsuperscript{32,33}. Under this hypothesis, HLA-B*38:01 and HLA-DRB1*08:01 might be good TiA candidates in Caucasians. On the other hand, other reasonable hypotheses exist, including different major HLA genes/alleles (such as in GD\textsuperscript{22} and in carbamazepine-induced Stevens–Johnson syndrome\textsuperscript{23}), a spectrum of HLA...
Figure 5 | Surface representation of HLA proteins and their sub-pockets.

(a) HLA-B*38:02. The pocket positions are defined on the basis of the crystal structures of peptide-HLA-B*15:01 complex. The sub-pockets of HLA-B*38:01 are located at similar positions. (b) HLA-DRA/DRB1*08:03. The pocket positions are defined on the basis of the crystal structure of peptide-HLA-DR1 complex.

genes/alleles sharing critical HLA amino-acid polymorphism (such as in rheumatoid arthritis\(^ {34} \)), or even non-genetic causes.

Methods

Study individuals. GD was diagnosed on the basis of the presence of clinical and biochemical hyperthyroidism together with either the presence of thyroid eye disease or a diffuse goitre and a significant titre of autoantibodies\(^ {22} \). Enrollment of GD individuals has been a continuous process at the National Taiwan University Hospital (NTUH) and at National Taiwan University Hospital, but has later been actively searched for from the medical records at NTUH. Medical records were reviewed and the patients were excluded if they noted that these cases were identified by clinical infection, not just by laboratory data. All the patients in this study presented with fever and sore throat with or without skin rash were hospitalized for management. Agranulocytosis developed approximately within 3 months after the start of ATDs. Available medical information of those 42 patients might not be sufficient to completely exclude concurrent viral infection. Causality assessment using widely adapted tools, such as the Naranjo algorithm\(^ {35, 36} \) and the World Health Organization Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (WHO-UMC) causality categories\(^ {37} \), scored 'probable' adverse drug reaction for all the 42 cases; the causality assessment did not reach the highest definite/certain category mostly because re-challenge test was not performed and it was not possible to completely exclude all other possible causes.

For TiA 'cases', we enrolled 21 patients at NTUH between 2001 and March 2012 and genotyped in our first-stage study (Supplementary Table 1). We used GD patients without agranulocytosis as the controls (GD controls). Our first-stage study comprised 497 unrelated GD patients and the 165 probands from unrelated GD cases and all 662 first-stage GD controls overplpped with the individuals reported in our previous paper\(^ {22} \). All the other TiA cases and the second-stage GD controls were new participants not previously reported. Power calculations were performed with various MAF and OR settings using QUANTO\(^ {37} \) (http://hyb2.euc.ops/Quanto.html). On the basis of the given sample size of the current GWAS study (TiA case number \(= 42 \), GD control number \(= 927 \)), the power was reasonably adequate to detect major susceptibility gene(s) (Supplementary Fig. 6). The study was approved by the Institutional Review Board of both NTUH and KCGMH. Written informed consent was obtained from all participants.

Direct HLA genotyping. There were four kinds of HLA genotyping methods used in this study including (1) Dynal RELI SSO typing kits (Dynal biotech Ltd, Bromborough, Wirral, UK, now part of Life Technologies, Carlsbad, CA, USA, http://www.invitrogen.com/), (2) Gold SSP HLA-DPB1 High-resolution Kit (Invitrogen Corp., now part of Life Technologies http://www.invitrogen.com/), (3) LABType SSO kit (One lambda Inc., Canoga Park, CA, USA, http://www.onelambda.com/) and (4) SeCore HLA Sequence-Based Typing Kit (Life Technologies Corporation, Brown Deer, WI, USA, http://www.lifetechnologies.com/). The first three methods were applied to 2 out of our 21 first-stage TiA cases and all of our 662 first-stage GD controls. The fourth method (SeCore HLA sequence-based typing) was applied to all (including both first-stage and second-stage) of our 42 TiA cases and all of our 546-s-stage GD controls. In addition to the first-stage TiA cases that were genotyped using more than one genotyping methods, we also randomly selected 24 first-stage GD controls to receive SeCore HLA sequence-based typing, in order to make sure that the genotyping results were consistent across all the genotyping methods.

Dynal RELI SSO genotyping was performed according to the manufacturer’s instructions. Briefly, PCR using locus-specific primer sets were applied to amplify both exon 2 and exon 3 of class I (HLA-A, -B and -C) genes or exon 2 of class II (-DQB1 and -DRB1) genes. Subsequently, PCR products were hybridized with sequence-specific oligonucleotide (SSO) probes previously fixed in a linear array on a nylon membrane (HLA-A: 48 probes, -B: 61 probes, -C: 37 probes, -DQB1: 41 probes and -DRB1: 60 probes). We then interpreted the genotypes using the Pattern Matching programme (Dynal biotech Ltd). Owing to the lack of the DPB1 genotyping kit in the Dynal RELI SSO system, we genotyped HLA-DPB1 based on a sequence-specific primer (SSP) amplification method using ‘Gold SSP HLA-DPB1 High resolution Kit’ according to the manufacturer’s protocol. Briefly, 48 PCR reactions were performed for each DNA sample. After PCR amplification and electrophoresis, the patterns of positive amplifications were used to interpret HLA-DPB1 genotypes with the company’s Unimatch software (Invitrogen Corp.).

LABType SSO kit-based genotyping was performed according to the manufacturer’s protocol. Briefly, PCR products were hybridized with probes bound to fluorescently coded microspheres (HLA-A: 58/61/63 probes, -B: 100 probes, -C: 56 probes, -DQB1: 40 probes, -DRB1: 37 probes and -DRB1: 70 probes). Subsequently, a flow analyser was used to identify the fluorescent intensity on each microsphere (LABType visual software; One lambda Inc.) and assignment of the HLA genotype was obtained on the basis of the reaction pattern.

SeCore HLA sequence-based typing was performed as follows. HLA-A, HLA-B, HLA-C and HLA-DPB1 polymorphism on exon 2, exon 3 and exon 4, HLA-DRA polymorphism on exon 2 and exon 3 were determined using the SeCore HLA Sequence-Based Typing Kit (Life Technologies Corporation) according to the manufacturer’s instructions. Briefly, after locus-specific PCR amplification, PCR products were treated with exonuclease I and shrimp alkaline phosphatase to remove excess dNTP and primers. The sequencing reaction for each exon was carried out using the Big Dye terminator v1.1 cycle sequencing kit in both directions. Sequencing was run on an automated ABI 3730 sequencer (Applied Biosystems, Foster City, CA, USA). The allele assignment was obtained by comparing the determined sequence with all combinations of known allele sequence in the IMGT/HLA database using the ABI sequencing analysis software (Life Technologies Corporation). In case of heterozygous individuals with genotype ambiguities in which several genotype combinations produced same sequencing result, allele designation was assigned according to the most common alleles found in Taiwanese population. Two-field designation with the new naming format was used to assign HLA types.

Genome-wide SNP genotyping and quality control. Genome-wide genotyping analysis was conducted using the Affymetrix Axiom Genome-Wide CHB 1 Array Plate with 642,832 SNPs (CapitalBio Co., Ltd, Beijing, China). Genome-wide
Genotypes were called by the Axiom GT1 algorithm. Systematic quality control was then performed for individuals and SNPs. For each individual genotyped in the GWAS study, quality control filtering for drug binding (Fig. 5), with the estimated binding activities in the range between –4.48 and –6.36 kcal mol⁻¹. To further confirm the binding poses of the drug molecules, 2ns molecular dynamics simulations were conducted for each complex system by Amber with the AMBER parm99SB (ref. 30) for proteins and the general amber forcefield33 for drugs. The molecular graphics figures were made by PyMOL 1.3 (Fig. 4) and UCSF Chimera 1.6.1 (Fig. 5).22

References

1. Weetman, A. P. Graves’ disease. N. Engl. J. Med. 343, 1236–1248 (2000).
2. Tunbridge, W. M. et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin. Endocrinol. (Oxf.) 7, 481–493 (1977).
3. Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84, 223–243 (1997).
4. Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905–917 (2005).
5. Tajiri, J. & Noguchi, S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 14, 459–462 (2004).
6. Nakamura, H., Miyauchi, A., Miyawaki, N. & Imagawa, J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J. Clin. Endocrinol. Metab. 98, 4776–4783 (2013).
7. Andersson, F., Konzen, C. & Garbe, E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann. Intern. Med. 146, 657–665 (2007).
8. Huber, M. et al. Drug-induced agranulocytosis in the Berlin case-control surveillance study. Eur. J. Clin. Pharmacol. 70, 339–345 (2014).
9. Edwards, I. R. & Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 355, 1255–1259 (2000).
10. Aronson, J. K. & Ferner, R. E. Joining the DoTs: new approach to classifying adverse drug reactions. Br. Med. J. 327, 1222–1225 (2003).
11. Wang, L., McLeod, H. L. & Weinshilboum, R. M. Genomics and drug response. N. Engl. J. Med. 364, 1144–1153 (2011).
12. Yunits, J. J. et al. HLA associations in clazapine-induced agranulocytosis. Blood 86, 1177–1183 (1995).
13. Tamai, H. et al. Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann. Intern. Med. 124, 490–494 (1996).
14. Valevski, A. et al. HLA-B38 and clazapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur. J. Immunogenet. 25, 11–13 (1998).
15. Oppen-Rhein, C. & Dettling, M. Clazapine-induced agranulocytosis and its genetic determinants. PharmGenomics 9, 1101–1111 (2008).
16. Zhang, J. P. & Malhotra, A. K. Pharmacogenomics of antipsychotics: recent progress and methodological issues. Expert Opin. Drug Metab. Toxicol. 9, 183–191 (2013).
17. Chung, W. H. et al. Medical genetici: a marker for Stevens-Johnson syndrome. N. Engl. J. Med. 428, 486 (2004).
18. Ozeki, T. et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034–1041 (2011).
19. Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121–1122 (2002).
20. Mallal, S. et al. Association between HLA-B*5701, HLA-DR7, and abacavir reactions in Japanese population. Hum. Mol. Genet. 18, 709–719 (2009).
21. Spraggs, C. F. et al. HLA-DQA1*0201 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667–673 (2011).
22. Chen, P. L. et al. Comprehensive genotyping in two homogeneous Graves’ disease samples reveals major and novel HLA association alleles. PLoS ONE 6, e16635 (2011).
23. Pavlos, R., Mallal, S. & Phillips, E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 13, 1285–1306 (2012).
24. Klein, J. & Sato, A. The HLA system. First of two parts. N. Engl. J. Med. 343, 702–709 (2000).
25. Lucena, M. L. et al. Susceptibility to aminoquinol-classavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141, 338–347 (2011).
26. Erlich, H. A., Opele, G. & Hansen, J. HLA DNA typing and transplantation. Immunology 14, 347–356 (2001).
27. Gonzalez-Galarza, F. E., Christians, S., Middleton, D. & Jones, A. R. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39, D913–D919 (2011).
28. Lieberman, J. A. et al. HLA-B83, DR4, DQw3 and clazapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch. Gen. Psychiatry 47, 945–948 (1990).
29. DeLuca, D. S. & Blasczyk, R. HistoCheck. Evaluating structural and functional MHC similarities. Methods Mol. Biol. 409, 395–405 (2007).
30. Huang, C. H., Li, K. L., Wu, J. H., Wang, P. N. & Jiang, J. H. Antithyroid drug-induced agranulocytosis: report of 13 cases. Chang Gung Med. J. 30, 242–248 (2007).

31. Sheng, W. H. et al. Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections. QJM 92, 455–461 (1999).

32. Noble, J. A. & Valdes, A. M. Genetics of the HLA region in the prediction of type 1 diabetes. Curr. Diab. Rep. 11, 533–542 (2011).

33. Pociot, F. & McDermott, M. F. Genetics of type 1 diabetes mellitus. Genes Immun. 3, 235–249 (2002).

34. Okada, Y. et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum. Mol. Genet. 23, 6916–6926 (2014).

35. Zaki, S. A. Adverse drug reaction and causality assessment scales. Lung India 28, 152–153 (2011).

36. Naranjo, C. A. et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30, 239–245 (1981).

37. Gauderman, W. J. Sample size requirements for association studies of gene interaction. Am. J. Epidemiol. 155, 478–484 (2002).

38. Huang, C. H., Li, K. L., Wu, J. H., Wang, P. N. & Juang, J. H. Antithyroid drug-induced agranulocytosis complicated by human leukocyte antigen genotyping and genome-wide association study. J. Immunol. 188, 235–249 (2002).

39. Chu, X. et al. A genome-wide association study identifies two new risk loci for Graves’ disease. Nat. Genet. 43, 897–901 (2011).

40. Jia, X. et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE 8, e64683 (2013).

41. Pillai, N. E. et al. Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations. Hum. Mol. Genet. 23, 4443–4451 (2014).

42. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725–738 (2010).

43. Eswar, N. et al. Comparative protein structure modeling using Modeller. Curr. Protoc. Bioinformatics Chapter 5, Unit 5–Unit 6 (2006).

44. Li, H., Robertson, A. D. & Jensen, J. H. Very fast empirical prediction and rationalization of protein pK(a) values. Proteins 61, 704–721 (2005).

45. Dolinsky, T. J., Nielsen, J. E., McCammon, J. A. & Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665–W667 (2004).

46. Hehre, W. J., Ditchfie, R. & Pople, J. A. Self-consistent molecular-orbital methods.12. Further extensions of Gaussian-type basis sets for use in molecular-orbital studies of organic-molecules. J. Chem. Phys. 56, 2257–2261 (1972).

47. Bayly, C. I., Cieplak, P., Cornell, W. D. & Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges - the resp model. J. Phys. Chem. 97, 10269–10280 (1993).

48. Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791 (2009).

49. Wang, J. C., Lin, J. H., Chen, C. M., Perryman, A. L. & Olson, A. J. Robust scoring functions for protein-ligand interactions with quantum chemical charge models. J. Chem. Inf. Model. 51, 2528–2537 (2011).

50. Hornak, V. et al. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65, 712–725 (2006).

51. Wang, J. M., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157–1174 (2004).

52. Pettersen, E. F. et al. UCSF chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).

Acknowledgements

We thank D. Valle and C.-H. Chen for helpful discussion and M. Liao and C.-C. Lin for technical support. We thank all the participants who provided DNA and clinical information necessary for this study. This work was supported by the following grants: 100-2314-B-002-118-MY3, 102-2314-B-001-003-MY2, 102-2325-B-002-034 , 102-2314-B-002-020-MY2 and NHRI-EX103-100232P. We thank the National Center for Genomic Medicine of the National Core Facility Program for Biotechnology, Ministry of Science and Technology, Taiwan, for the technical/bioinformatics support. We thank the Translational Resource Center for Genomic Medicine of National Research Program for Biopharmaceuticals (NRPB), Taiwan. We are grateful to the National Center for High-performance Computing (NCHC), Taiwan, for computer time and facilities.

Author contributions

P.-L.C., C.-S.J.F., W.-S.Y. and T.-C.C. obtained financial support and conceived and designed the study. S.-R.S., P.-W.W. and S.-C.C. supervised all the sample collection. P.-L.C., S.-R.S., P.-W.W., S.-C.C., Ching-Chung C., T.-S.H., K.S.T., F.-Y.T., C.-Y.W., J.-Y.L., W.-Y.C., W.-S.Y. and T.-C.C. assessed clinical features, participated in diagnostic evaluation and recruited subjects. P.-L.C., Chien-Ching C., Yu-Chih L. and C.-C.Chu and C.-S.J.F. performed genotyping, data analyses and interpretation. J.-H.L. and Y.-H.C. performed computational 3D structure modelling. P.-L.C., Chien-Ching C. and C.-C.Chu wrote the first draft of the manuscript. Yu-Chih L., C.-S.J.F., W.-S.Y., Y.-T.C. and T.-C.C. revised the manuscript. All authors contributed to writing the final manuscript.

Additional information

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Chen, P.-L. et al. Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study. Nat. Commun. 6:7633 doi: 10.1038/ncomms8633 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/